Compare FRSH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSH | PHVS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2021 | 2020 |
| Metric | FRSH | PHVS |
|---|---|---|
| Price | $8.72 | $33.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | $14.86 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 14.1M | 301.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 296.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $838,809,000.00 | N/A |
| Revenue This Year | $16.30 | N/A |
| Revenue Next Year | $14.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.43 | N/A |
| 52 Week Low | $6.79 | $16.72 |
| 52 Week High | $15.47 | $34.41 |
| Indicator | FRSH | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 60.08 |
| Support Level | $7.71 | $24.73 |
| Resistance Level | $9.40 | $33.33 |
| Average True Range (ATR) | 0.46 | 1.60 |
| MACD | -0.10 | 0.18 |
| Stochastic Oscillator | 11.59 | 72.94 |
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.